Corrigendum to “Sustained superior humoral immune responses of mRNA vaccines compared to Sputnik V viral vector COVID-19 vaccines in naïve and convalescent populations” [Vaccine 70 (2026) 128018]
Vaccine. 2026 Feb 14;77:128333. doi: 10.1016/j.vaccine.2026.128333. Online ahead of print.
PMID:
Post-tuberculosis lung disease and pulmonary aspergillosis management: challenges and considerations
Expert Rev Anti Infect Ther. 2026 Feb 22:1-21. doi: 10.1080/14787210.2026.2631525. Online ahead of print.
PMID:
B Lymphocyte Protein Factories produced by Hematopoietic Stem Cell Gene Editing
bioRxiv [Preprint]. 2026 Jan 18:2026.01.16.699998. doi: 10.64898/2026.01.16.699998.
PMID:
One-year clinical outcome of PreserFlo MicroShunt implantation versus trabeculectomy in patients with secondary open-angle glaucoma
Can J Ophthalmol. 2026 Feb 18:S0008-4182(26)00002-5. doi: 10.1016/j.jcjo.2026.01.002. Online ahead of print.
PMID:
Effect of in-hospital and post-discharge complications on 1-year functional outcome after stroke and transient ischemic attack
Eur Stroke J. 2026 Jan 1;11(1):23969873251383315. doi: 10.1093/esj/23969873251383315.
PMID:
An H5N1 clade 2.3.4.4b virus vaccine that elicits cross-protective antibodies against conserved domains of H5 and N1 glycoproteins
Nat Commun. 2026 Jan 23;17(1):1749. doi: 10.1038/s41467-026-68457-6.
PMID:
Cross-binding antibodies capable of neutralising diverse hantaviruses are produced in response to Puumala virus infection
EBioMedicine. 2026 Feb;124:106091. doi: 10.1016/j.ebiom.2025.106091. Epub 2026 Jan 8.
PMID:
Evaluating modes of influenza transmission (EMIT-2): Insights from lack of transmission in a controlled transmission trial with naturally infected donors
PLoS Pathog. 2026 Jan 7;22(1):e1013153. doi: 10.1371/journal.ppat.1013153. eCollection 2026 Jan.
PMID:
Structural and functional characterization of the antigenicity of influenza A virus hemagglutinin subtype H15
Cell Rep. 2026 Jan 27;45(1):116773. doi: 10.1016/j.celrep.2025.116773. Epub 2026 Jan 2.
PMID:
Ligand-receptor interactions of V-domain Ig-containing suppressor of T cell activation and programmed death-1 suppress the anticancer activities of T cells
Immunooncol Technol. 2025 Nov 13;28:101533. doi: 10.1016/j.iotech.2025.101533. eCollection 2025 Dec.
PMID: